Pionyr Immunotherapeutics
2 Tower Pl, Suite 800
South San Francisco
CA
94080
United States
Tel: (650) 825-6140
Website: http://www.pionyrtx.com/
Email: info@pionyrtx.com
8 articles with Pionyr Immunotherapeutics
-
Pionyr Immunotherapeutics Adds Three Leading Oncology Researchers and Drug Developers to Scientific Advisory Board
5/3/2022
Pionyr Immunotherapeutics, Inc. announced today that Johanna Joyce, Ph.D., Olivier Elemento, Ph.D., and Michael Quigley, Ph.D., will join Miriam Merad, Ph.D., as members of Pionyr’s Scientific Advisory Board.
-
Pionyr Immunotherapeutics Doses First Patient in Phase 1b Expansion Study of PY314
3/8/2022
Pionyr Immunotherapeutics, Inc. announced that the first patient has been dosed in Phase 1b expansion studies investigating PY314 in patients with solid tumors.
-
Pionyr Immunotherapeutics Collaborates with Lonza to Support their Oncology Product Development
3/29/2021
The collaboration with Pionyr Therapeutics demonstrates Lonza’s flexibility to tailor its offering to accommodate the specific needs of our customers. Our team has created a cell line development program relying on a state-of-the-art platform technology that brings a faster and streamlined approach to selecting an ideal cell line.
-
PIONYR Immunotherapeutics Initiates Phase 1 Clinical Study Of PY314
11/18/2020
Pionyr Immunotherapeutics, Inc., a company developing first-in-class antibody therapeutics that increase the body's antitumor immunity by altering the composition and function
-
Today, Gilead announced that it was acquiring a 49.9% equity interest in Pionyr Immunotherapeutics for $275 million and exclusive option to buy the rest of the company.
-
PIONYR Immunotherapeutics Announces Key Leadership Team Addition and Clinical Candidates Targeting Tumor-Associated Macrophages
8/27/2019
PIONYR Immunotherapeutics, Inc. announced the appointment of Alicia Levey, Ph.D., as Senior Vice President and Chief Business Officer.
-
ProBioGen and Pionyr Immunotherapeutics Initiate a Second Immuno-oncology Contract Development and Manufacturing Project
7/10/2018
ProBioGen AG and Pionyr Immunotherapeutics, today announced a second service and license agreement to develop novel antibody therapeutics.
-
Pionyr was founded in 2015 by a UCSF professor and a Genentech alum.